TrialAntimicrobial agents and chemotherapy2021

Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study.

Xiaojie Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.